C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H1 2018
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H1 2018
SUMMARY
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor also plays an important role in trafficking of dendritic cells. The CC chemokines CCL3, CCL5, CCL17 and CCL22 signal through this receptor.
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.The molecules developed by companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively.
Report covers products from therapy areas Oncology, Central Nervous System and Immunology which include indications Solid Tumor, T-Cell Lymphomas, Autoimmune Disorders, Breast Cancer, Cutaneous T-Cell Lymphoma, Epithelial Tumor, Gastric Cancer, Hematological Tumor, Mycosis Fungoides, Myelopathy, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Sezary Syndrome, T-Cell Leukemia and Tropical Spastic Paraparesis.
The latest report C-C Chemokine Receptor Type 4 - Pipeline Review, H1 2018, outlays comprehensive information on the C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
It also reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor also plays an important role in trafficking of dendritic cells. The CC chemokines CCL3, CCL5, CCL17 and CCL22 signal through this receptor.
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.The molecules developed by companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively.
Report covers products from therapy areas Oncology, Central Nervous System and Immunology which include indications Solid Tumor, T-Cell Lymphomas, Autoimmune Disorders, Breast Cancer, Cutaneous T-Cell Lymphoma, Epithelial Tumor, Gastric Cancer, Hematological Tumor, Mycosis Fungoides, Myelopathy, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Sezary Syndrome, T-Cell Leukemia and Tropical Spastic Paraparesis.
The latest report C-C Chemokine Receptor Type 4 - Pipeline Review, H1 2018, outlays comprehensive information on the C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
It also reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)
- The report reviews C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Overview
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Companies Involved in Therapeutics Development
Affitech A/S
Corion Biotech Srl
FLX Bio Inc
Kyowa Hakko Kirin Co Ltd
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Drug Profiles
AT-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBChMF-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FLX-475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mogamulizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target CCR4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Dormant Products
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Discontinued Products
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Product Development Milestones
Featured News & Press Releases
Dec 11, 2017: Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma at the American Society of Hematology 2017
Nov 30, 2017: Kyowa Hakko Kirin Submits the Partial Change Approval Application of Mogamulizumab in Japan
Nov 28, 2017: Kyowa Hakko Kirin Announces FDA Acceptance for Filing and Priority Review Designation of Mogamulizumab's Biologics License Application
Oct 27, 2017: Kyowa Hakko Kirin Announces Marketing Authorization Application for Mogamulizumab Validated by European Medicines Agency
Sep 21, 2017: FLX Bio Selects Immuno-Oncology Clinical Candidate
Aug 25, 2017: US Food and Drug Administration Grants Breakthrough Therapy Designation for Mogamulizumab for the Treatment of Mycosis Fungoides and Sezary Syndrome
Jun 30, 2017: Kyowa Hakko Kirin Announces Initiation of Phase 3 Study in Japan of Mogamulizumab in Patients with HTLV-1 Associated Myelopathy
Apr 07, 2017: Kyowa Hakko Kirin Announces Positive Results of the Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma
Mar 31, 2017: FLX Bio to Present Poster at the American Association of Cancer Research Conference on its Lead Immuno-Oncology Program Targeting CCR4
Jun 06, 2016: Kyowa Hakko Kirin Announces Preliminary Results from Pivotal Phase 2 Study of Mogamulizumab (KW-0761) in Patients with Relapsed or Refractory Adult T-cell Leukemia-Lymphoma
Jul 29, 2015: Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S.
Dec 18, 2014: Approval for Additional Indication for Chemotherapy-Native CCR4-positive ATL of Mogamulizumab
Dec 10, 2014: Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab in Advanced Solid Tumors
Sep 29, 2014: Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study
Jun 30, 2014: Reapplication Seeking Approval for Additional Indication for ATL of Mogamulizumab
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Overview
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Companies Involved in Therapeutics Development
Affitech A/S
Corion Biotech Srl
FLX Bio Inc
Kyowa Hakko Kirin Co Ltd
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Drug Profiles
AT-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBChMF-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FLX-475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mogamulizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target CCR4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Dormant Products
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Discontinued Products
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Product Development Milestones
Featured News & Press Releases
Dec 11, 2017: Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma at the American Society of Hematology 2017
Nov 30, 2017: Kyowa Hakko Kirin Submits the Partial Change Approval Application of Mogamulizumab in Japan
Nov 28, 2017: Kyowa Hakko Kirin Announces FDA Acceptance for Filing and Priority Review Designation of Mogamulizumab's Biologics License Application
Oct 27, 2017: Kyowa Hakko Kirin Announces Marketing Authorization Application for Mogamulizumab Validated by European Medicines Agency
Sep 21, 2017: FLX Bio Selects Immuno-Oncology Clinical Candidate
Aug 25, 2017: US Food and Drug Administration Grants Breakthrough Therapy Designation for Mogamulizumab for the Treatment of Mycosis Fungoides and Sezary Syndrome
Jun 30, 2017: Kyowa Hakko Kirin Announces Initiation of Phase 3 Study in Japan of Mogamulizumab in Patients with HTLV-1 Associated Myelopathy
Apr 07, 2017: Kyowa Hakko Kirin Announces Positive Results of the Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma
Mar 31, 2017: FLX Bio to Present Poster at the American Association of Cancer Research Conference on its Lead Immuno-Oncology Program Targeting CCR4
Jun 06, 2016: Kyowa Hakko Kirin Announces Preliminary Results from Pivotal Phase 2 Study of Mogamulizumab (KW-0761) in Patients with Relapsed or Refractory Adult T-cell Leukemia-Lymphoma
Jul 29, 2015: Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S.
Dec 18, 2014: Approval for Additional Indication for Chemotherapy-Native CCR4-positive ATL of Mogamulizumab
Dec 10, 2014: Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab in Advanced Solid Tumors
Sep 29, 2014: Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study
Jun 30, 2014: Reapplication Seeking Approval for Additional Indication for ATL of Mogamulizumab
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Affitech A/S, H1 2018
Pipeline by Corion Biotech Srl, H1 2018
Pipeline by FLX Bio Inc, H1 2018
Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Affitech A/S, H1 2018
Pipeline by Corion Biotech Srl, H1 2018
Pipeline by FLX Bio Inc, H1 2018
Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Affitech A/S
Corion Biotech Srl
FLX Bio Inc
Kyowa Hakko Kirin Co Ltd
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Affitech A/S
Corion Biotech Srl
FLX Bio Inc
Kyowa Hakko Kirin Co Ltd
